Cell Source, Inc. (CLCS)
OTCMKTS
· Delayed Price · Currency is USD
0.3115
+0.0125 (4.18%)
May 2, 2025, 2:16 PM EDT
Cell Source Company Description
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance.
Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.
The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases.
Cell Source, Inc. is headquartered in New York, New York.
Cell Source, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Itamar Shimrat |
Contact Details
Address: 57 West 57th Street New York, Nevada 10019 United States | |
| Phone | 646 416 7896 |
| Website | cell-source.com |
Stock Details
| Ticker Symbol | CLCS |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US15114L1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Itamar Shimrat | Chief Executive Officer, President and Chief Financial Officer |
| Dr. Dennis M. Brown B.Sc., M.A., Ph.D. | Executive Chairman |